Samsung Bioepis submits biologic application of Herceptin biosimilar in U.S.

Samsung Bioepis(CEO/President Han-Seung Ko) is getting ready to target the U.S. market followed by the European one with ‘SB3(generic name: trastuzumab, European name: ontruzant),’ a biosimilar for the treatment of breast cancer.

Samsung Bioepis announced the U.S. Food and Drug Administration(FDA) has started to assess the Biologics License Application(BLA) of its breast cancer biosimilar SB3 ...